Vaccination against the hepatitis A virus (HAV) in children two years of age and younger remains effective for at least 10 years, according to new research available in the August issue of Hepatology, a journal of the American Association for the Study of Liver Diseases (AASLD). The study found that any transfer of the mother's HAV antibodies does not lower the child's immune response to the vaccine.
The World Health Organization (WHO) estimates that 1.4 million cases of HAV occur worldwide each year. HAV affects the liver and typically occurs in areas with poor sanitation where ingestion of contaminated food or water can transmit the virus. In the U.S., HAV cases have decreased by 90 percent in the past 20 years, with roughly 20,000 new cases reported each year according to the Centers for Disease Control and Prevention (CDC). Experts attribute the decline in HAV cases in the U.S. to routine vaccination of children 12 to 18 months.
According to lead author Dr. Umid Sharapov, an epidemiologist with the CDC and his coauthors, this is the first study to examine the effectiveness of a two-dose inactivated hepatitis A vaccine in children younger than two years of age over a ten-year period. In addition, the researchers investigated whether maternal anti-HAV antibody transfer to their children impacts the vaccine protection against HAV.
With parental consent, researchers enrolled full-term infants who were healthy at six-months of age. Mothers were tested for total antibody to HAV. The 197 infants and toddlers were broken into three age groups: group one-infants 6 to 12 months; group two-toddlers between 12 and 18 months; and group three-toddlers 15 to 21 months of age. Each group was randomized by maternal anti-HAV status. HAV antibody levels were measured at one and six months, and additional follow-up took place at three, five, seven and 10 years after the second dose of hepatitis A vaccine.
At one month following the second dose of the hepatitis A vaccine children in all groups showed signs of protection from the virus. At the 10-year follow-up most children retained anti-HAV protection. In the first group, 7 percent and 11 percent of children born to mother's without and with antibodies to the HAV virus, did not retain HAV protection from vaccination, respectively. Additionally, 4 percent of group three children born to anti-HAV negative mothers lost HAV protection.
"Our study demonstrates that seropositivity to hepatitis A persists for at least 10 years after primary vaccination with two-dose inactivated HAV vaccine when administered to children at ages 12 months and older, regardless of their mothers' anti-HAV status," concludes Sharapov. "These findings support current CDC/ACIP guidelines for routine administration of two doses of inactivated hepatitis A vaccine to all children in the U.S. beginning at the age of 12 months."
The authors point out that a future booster dose may be necessary to maintain protection against HAV and they will continue follow-up participants into their teens to monitor benefit of the initial immunization.
Reference: "Persistence of Hepatitis A Vaccine Induced Seropositivity in Infants and Young Children by Maternal Antibody Status: 10-Year Follow-Up." Umid M. Sharapov, Lisa R. Bulkow, Susan E. Negus, Philip R. Spradling, Chriss Homan, Jan Drobeniuc, Michael Bruce, Saleem Kamili, Dale J. Hu, Brian J. McMahon. Hepatology; DOI: 10.1002/hep.25687); Print Issue Date: August, 2012.
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
US Withdrawal From UNESCO Signals a Dangerous Step Back for Global Science
July 22nd 2025In a decision heavy with consequence and light on foresight, the US has once again chosen to walk away from UNESCO, leaving behind not just a seat at the table, but a legacy of global scientific leadership that now lies in question.
Breaking the Cycle of Silence: Why Sharps Injuries Go Unreported and What Can Be Done
Published: July 24th 2025 | Updated: July 23rd 2025Despite decades of progress in health care safety, a quiet but dangerous culture still lingers: many health care workers remain afraid to report sharps injuries, fearing blame more than the wound itself.
Telemedicine's Transformative Role in PPE Distribution and Sterile Equipment Management
July 22nd 2025In an era defined by digital transformation and post-pandemic urgency, telemedicine has evolved beyond virtual visits to become a vital infrastructure for delivering personal protective equipment (PPE) and managing sterile supplies. By enabling real-time forecasting, remote quality control, and equitable distribution, telemedicine is revolutionizing how health care systems protect both patients and providers.
Reducing Hidden Risks: Why Sharps Injuries Still Go Unreported
July 18th 2025Despite being a well-known occupational hazard, sharps injuries continue to occur in health care facilities and are often underreported, underestimated, and inadequately addressed. A recent interview with sharps safety advocate Amanda Heitman, BSN, RN, CNOR, a perioperative educational consultant, reveals why change is overdue and what new tools and guidance can help.